CHICAGO, April 6 /PRNewswire/ -- NanoInk, Inc., today announced that the Company's President and Chief Executive Officer, Dr. Cedric Loiret-Bernal will be a featured guest speaker at the BIO 2006 Annual International Convention being held in Chicago. (Photo: http://www.newscom.com/cgi-bin/prnh/20060406/CGTH068 Logo: http://www.newscom.com/cgi-bin/prnh/20030418/NANOLOGO ) Dr. Loiret-Bernal, a leading expert on nanoencryption, will speak about the Company's Nanoencryption(TM) technology and its use by pharmaceutical customers and DPN(R) technology for bio-nanoarrays. The presentation will begin at 9:30 a.m. CDT on Wednesday, April 12, 2006, in Room C, McCormick Place South, Level 3, Exhibit Hall A of the McCormick Place Convention Center. The McCormick Place Convention Center is located at 2301 South Lake Shore Drive, Chicago, IL. Dr. Loiret-Bernal is the former Chief Executive Officer and co-founder of GeneProt, Inc., and has also held many other senior positions in the pharmaceutical and biomedical industries at Abbott Laboratories, Haemonetics, and Porges-Synthelabo. Dr. Loiret-Bernal holds a doctor of medicine degree, summa cum laude, from the University of Bordeaux and has an MBA degree from the J.L. Kellogg School of Management, Northwestern University. "BIO 2006 is a wonderful opportunity to share the potential value of our proprietary Nanoencryption(TM) technology that helps prevent counterfeit and illegal pharmaceuticals from entering the global markets," said Dr. Loiret-Bernal. "I will also discuss the potential of our DPN(R) technology that enables the deposition of a variety of biomolecules for the development of bio-nanoarrays." Nanoencryption(TM) technology is the one-stop, deeply covert encryption and authentication solution to prevent counterfeit pharmaceuticals from entering the market. Counterfeit pharmaceuticals can be easily identified by the absence of special coded nanoencryption. During the authentication process, illegal products are flagged as mismatches and removed from the supply chain. Using NanoInk's proprietary technology, pharmaceutical manufacturers and enforcement agencies can identify and significantly reduce counterfeiting and illegal diversion. NanoInk's Scientific Founder, Chad A. Mirkin, Ph.D., Director of the International Institute of Nanotechnology, George B. Rathmann Professor of Chemistry, Professor of Medicine, Professor of Material Sciences & Engineering, Northwestern University, will discuss his most recent DPN(R) research work at The Illinois Pavilion, McCormick Place Convention Center, at 3 pm CDT, on Tuesday, April 11, 2006. During this presentation, his work will be recognized with an award presented by the Illinois Biotech Organization (iBIO). About NanoInk NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the lifescience and semiconductor industries. With DPN(R), a patented and proprietary nanofabrication technology that allows for unmatched flexibility, accuracy and also its high-resolution Nanoencryption(TM) technology, NanoInk is able to offer its pharmaceutical customers innovative solutions to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products. Other key applications include nanoscale additive repair, and nanoscale rapid prototyping. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 100 patents and patent applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, and the University of Illinois at Urbana-Champaign. For more information on products and services offered by NanoInk, Inc., see http://www.nanoink.net .
SOURCE NanoInk, Inc.